Company Overview
Vivos Therapeutics, Inc. operates within the healthcare sector, specifically functioning as a medical technology company focused on developing and commercializing treatment modalities for patients suffering from dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. The company's primary commercial offering, known as The Vivos Method, represents a non-invasive, non-surgical, and non-pharmaceutical approach designed to address these specific patient needs without the use of pharmaceutical interventions. In terms of scale, Vivos Therapeutics holds a market capitalization of $13.13M and employs a workforce of 262 individuals to support its operations and product development initiatives. The annual revenue for the trailing twelve months stands at $17.32M, a figure that, when combined with the relatively small market cap, indicates that the company is positioned as a micro-cap entity with significant room for expansion but currently operates with limited total market presence.
Financial Health
For the trailing twelve months, the company reported a revenue of $17.32M, while the net income was -$17,103,000 and the EBITDA amounted to -$15,307,000. The substantial gap between the positive revenue of $17.32M and the significant net loss of $17.103M reveals a cost structure where operating expenses and other deductions are nearly equal to total revenue generation, resulting in minimal profitability on a bottom-line basis. The free cash flow for the period was -$9,380,750, which indicates that the company is burning cash and lacks immediate financial flexibility to fund operations without additional capital injections or financing events. Analysis of the three margin metrics shows a gross margin of 55.7%, suggesting that the cost of goods sold is managed efficiently relative to revenue, yet an operating margin of -69.8% and a profit margin of -98.8% demonstrate that overhead costs and general expenses are consuming the vast majority of the company's income. On the balance sheet, the company holds $3.09M in cash against $12.50M in debt, resulting in a debt-to-equity ratio of 493.60, which characterizes the financial position as highly leveraged rather than conservative. The current ratio stands at 0.78, a metric that indicates the company possesses less current assets than current liabilities, signaling potential challenges in meeting short-term obligations without refinancing or asset liquidation. Furthermore, the return on equity is -335.5% and the return on assets is -49.8%, metrics that reveal that management effectiveness has been negative, as the company is currently destroying value per share of equity and per unit of asset deployed.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, whereas the forward P/E is calculated at -0.92; the disparity between these figures implies that the market is pricing in future earnings recovery but currently operates with a negative earnings expectation based on forward models. The price-to-book ratio is 3.76, a figure that indicates the market is valuing the company at a significant premium over its net book value, suggesting high expectations for future asset appreciation or intangible value despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 0.76 and the EV/EBITDA of -1.29 suggest that the valuation is being driven primarily by revenue multiples rather than earnings power, as the negative EV/EBITDA reflects the company's inability to generate earnings before interest, taxes, depreciation, and amortization. Regarding trading ranges, the stock has a 52-week high of $7.95 and a 52-week low of $1.11, meaning the current price sits significantly closer to the low end of this historical range compared to the high. The beta value is 7.02, which indicates that the stock price exhibits extreme volatility relative to the broader market, moving with a magnitude seven times greater than the market index during periods of fluctuation.
Growth & Income
The company demonstrated a revenue growth of 75.7% year-over-year, while the earnings growth is listed as N/A due to the absence of positive earnings in the trailing period. Because the earnings growth is N/A rather than a negative percentage, the implication is that earnings are not growing faster than revenue in a traditional sense but are instead constrained by the company's structural losses, preventing a clear growth trajectory in profitability. Vivos Therapeutics does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available funds, or in this case, retains losses, into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by rapid top-line expansion coupled with significant cash burn and an absence of income distribution, highlighting a strategy focused on market capture and product development rather than immediate shareholder returns.